Risk factors for drug-resistant epilepsy in adult patients.

Anti-seizure medications Anticonvulsivos Drug-resistant epilepsy Drug-sensitive epilepsy Epilepsia farmacorresistente Epilepsia refractaria Epilepsia sensible a fármacos Farmacorresistencia Pharmacoresistance Refractory epilepsy

Journal

Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377

Informations de publication

Date de publication:
23 06 2023
Historique:
received: 16 01 2023
revised: 10 03 2023
accepted: 15 03 2023
medline: 13 6 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Drug-resistant epilepsy occurs in about 30% of epilepsy patients. It has been suggested that etiology or seizure type would increase the risk of pharmacoresistance. This study aims to compare the characteristics of patients with drug-sensitive epilepsy with patients with drug-resistant epilepsy to identify risk factors. A multicentric cohort study was conducted between 2019 and 2022. We included patients >18 years-old with epilepsy but excluded psychogenic non-epileptic seizures and less than 2 years of follow-up. We included 128 patients, of whom 46 had drug-resistance epilepsy, and 82 responding to medication. Both groups showed similar characteristics. Febrile seizures (OR: 7.25), focal epilepsy (OR: 2.4), focal seizures with loss of consciousness (OR: 2.36), structural etiology (OR: 2.2) and abnormal MRI (OR: 4.6) were significant risk factors for drug-resistance epilepsy. Following other studies, we observed that factors such as epilepsy type, seizure type, structural etiology, abnormal MRI, and febrile seizure increased the risk for drug-resistance epilepsy, in our population.

Identifiants

pubmed: 37045668
pii: S0025-7753(23)00141-0
doi: 10.1016/j.medcli.2023.03.006
pii:
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article Multicenter Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

547-550

Informations de copyright

Copyright © 2023 Elsevier España, S.L.U. All rights reserved.

Auteurs

Ignacio Lagger (I)

Instituto de Investigaciones Biomédicas (BIOMED), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Pontificia Universidad Católica Argentina, Ciudad Autónoma de Buenos Aires, Argentina; Departamento de Neurología, Hospital General de Agudos Dr. Teodoro Álvarez, Ciudad Autónoma de Buenos Aires, Argentina.

Eliana Garino (E)

Departamento de Neurología, Hospital General de Agudos Dr. Teodoro Álvarez, Ciudad Autónoma de Buenos Aires, Argentina.

Oscar Martinez (O)

Departamento de Neurología, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Eduardo Knorre (E)

Departamento de Neurología, Hospital General de Agudos Dr. Teodoro Álvarez, Ciudad Autónoma de Buenos Aires, Argentina.

Glenda Ernst (G)

Comité Científico, Hospital Británico de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.

Adriana Laura Burgueño (AL)

Instituto de Investigaciones Biomédicas (BIOMED), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Pontificia Universidad Católica Argentina, Ciudad Autónoma de Buenos Aires, Argentina. Electronic address: alburgueno@uca.edu.ar.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH